Tyra Corp (TYRA) - Market Cap to Net Income Ratio

Symbol and logo of brand Tyra Biosciences Inc (TYRA)

Tyra Biosciences, Inc. (TYRA) has an adjusted P/E comparable to its strategy for combating tumor resistance and treating pediatric dysplasias. The -8.20 value shows the latest metric reading, helping to avoid overpaying for the asset. This chart confirms the intensity of clinical programs targeting bladder cancer. Developments are based on AI-driven design of targeted FGFR inhibitors, ensuring a scientific priority in precision oncology.

TYRA tyra.bio: Price to Earnings Ratio in the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for Tyra Corp (TYRA)

- market price and analyst price targets:
Comprehensive company analysis:Tyra Biosciences - TYRA
Finished products of Tyra Bio

Speculative expectations regarding the Phase 2 clinical trial results of the FGFR inhibitor are already priced into the shares of Tyra Biosciences, Inc. (TYRA), making the company's estimated P/E analysis a key tool for verifying market optimism. This multiple, reflecting the ratio of market capitalization to net income, allows for the timely identification of systemic risks and asset overvaluation, preventing capital from being frozen should the company fail to achieve its fundamental goals.